A review on the advancements in the development of vaccines to combat coronavirus disease 2019

다국어 초록 (Multilingual Abstract)

Coronavirus disease 2019 (COVID-19), the deadly disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a global pandemic that has severely affected lives and economies around the globe. The spread of this virus will be very difficult to contain if no vaccine is ready for implementation. This is because of the high human-to-human transmission rate of this virus and the fact that the virus is in the community spread stage. As of 31st August 2020, 25.3 million individuals have been affected by this deadly virus resulting in about 850,673 deaths. To combat the spread of COVID-19, more than 100 applicant immunizations are being developed around the world. Among them, eight have begun or will be soon beginning preliminary clinical trials. This paper provides a review of the current developments of potential COVID-19 vaccines around the world. It specifically discusses the recombinant vaccine produced by the University of Oxford and AstraZeneca (Cambridge, UK), the use of novel self-amplifying RNA technique to create a vaccine and the progress made by UNAID (US National Institute of Allergy and Infectious Diseases) and World Health Organization (WHO). Furthermore, this review demonstrates the pharmaceutical prophylaxis and treatment protocols for COVID-19 by analysing the documentation set up by the WHO for up to date data with respect to the novel coronavirus of 2019–2020.

참고문헌 (Reference)

1 World Health Organization, "“Solidarity” clinical trial for COVID-19 treatments" World Health Organization

2 European Medicines Agency, "Update on treatments and vaccines against COVID-19 under development" European Medicines Agency

3 Shen C, "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma" 323 : 1582-1589, 2020

4 Duan K, "The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study"

5 Gudbjartsson DF, "Spread of SARS-CoV-2 in the Icelandic population" 382 : 2302-2315, 2020

6 Zhu FC, "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial" 395 : 1845-1854, 2020

7 Amanat F, "SARS-CoV-2 vaccines : status report" 52 : 583-589, 2020

8 Beigel JH, "Remdesivir for the treatment of COVID-19 : final report" 383 : 1813-1826, 2020

9 "Randomised Evaluation of COVID-19 Therapy. Statement from the chief investigators of the randomised evaluation of COVID-19 therapy (RECOVERY) trial on lopinavir-ritonavir" Nuffield Department of Population Health University of Oxford

10 "Randomised Evaluation of COVID-19 Therapy. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19" Nuffield Department of Population Health University of Oxford

11 Boseley S, "Oxford offers best hope for COVID-19 vaccine this year, MPs told"

12 Inserm Press Office, "Launch of a European clinical trial against COVID-19"

13 U.S. Food and Drug Administration, "Investigational COVID-19 convalescent plasma: emergency INDs" U.S. Food and Drug Administration

14 Al-Mashhadani SH, "Investigating the spread of coronavirus(COVID-19)at airports and methods of protection" 24 (24): 37-43, 2020

15 Cowling BJ, "Impact assessment of nonpharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong : an observational study" 5 : e279-e288, 2020

16 Radcliffe S, "Here’s exactly where we are with vaccines and treatments for COVID-19" Healthline

17 European Medicines Agency, "First COVID-19 treatment recommended for EU authorisation" European Medicines Agency

18 Liu A, "FiercePharmaAsia: Daiichi’s win-lose week; Astra’s China business; Novavax-Fujifilm COVID-19 vax deal" Fierce Pharma

19 "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID 19. COVID-19 expanded access program: plasma donors needed for treatment protocol" Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

20 Horby P, "Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report"

21 Joyner M, "Early safety indicators of COVID-19 convalescent plasma in 5,000 patients"

22 European Medicines Agency, "EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19" European Medicines Agency

23 European Medicines Agency, "EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic" European Medicines Agency

24 World Health Organization, "Draft landscape and tracker of COVID-19 candidate vaccines" World Health Organization

25 RECOVERY Collaborative Group, "Dexamethasone in Hospitalized Patients with Covid-19" Massachusetts Medical Society 384 (384): 693-704, 2021

26 Kirby T, "Development of potential COVID-19 vaccines continues to accelerate" 1 : e109-, 2020

27 European Commission, "Daily news 03/07/2020: European Commission authorises first treatment against COVID-19" European Commission

28 COVID-19 Treatment Guidelines Panel, "Coronavirus disease 2019 (COVID-19) treatment guidelines" National Institutes of Health

29 Liu ST, "Convalescent plasma treatment of severe COVID-19: a matched control study"

30 Worldometer, "COVID-19 coronavirus pandemic"

31 Speights K, "Better coronavirus stock: Novavax vs. Quidel" The Motley Fool

32 European Commission, "An EU programme of COVID-19convalescent plasma collection and transfusion: guidance on collection, testing, processing, storage, distribution and monitored use" European Commission

33 Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19" 382 : 1787-1799, 2020

34 Al-Sharify NT, "A technical overview and comparison between PET and MRI scanning" 11 : 35-41, 2020

35 Boulware DR, "A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19" 383 : 517-525, 2020

36 Al-Sharify ZT, "A critical review on medical imaging techniques(CT and PET scans)in the medical field" 870 : 012043-, 2020